TOP TEN perturbations for 1553478_at (Homo sapiens)
Organism: Homo sapiens
Gene: 1553478_at
Selected probe(set): 1553478_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1553478_at (1553478_at) across 6537 perturbations tested by GENEVESTIGATOR:
strabismus study 1 / normal extraocular medial rectus muscle tissue
Relative Expression (log2-ratio):-0.9939203Number of Samples:3 / 4
| Experimental | strabismus study 1 |
| Human extraocular medial rectus muscle tissue sample obtained from patients with strabismus after strabismus correction surgery. | |
| Control | normal extraocular medial rectus muscle tissue |
| Postmortem human extraocular medial rectus tissue samples from healthy donors without any ophthalmologic disease. |
tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample
Relative Expression (log2-ratio):-0.93181133Number of Samples:3 / 3
| Experimental | tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 DICER1(-/-) cell sample |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
engineered skin substitute study 2 (intermediate) / engineered skin substitute study 1 (intermediate)
Relative Expression (log2-ratio):0.908761Number of Samples:6 / 3
| Experimental | engineered skin substitute study 2 (intermediate) |
| Human skin substitutes tissue samples collected after 14 and 28 days after transplantation to athymic mice. | |
| Control | engineered skin substitute study 1 (intermediate) |
| Human skin substitutes tissue samples collected after 7 days in culture. |
HCC study 27 (young; validation) / HCC study 27 (elder; validation)
Relative Expression (log2-ratio):-0.90636826Number of Samples:21 / 10
| Experimental | HCC study 27 (young; validation) |
| Primary tumor tissue samples obtained from the liver of young patients (≤ 40 years old) with hepatocellular carcinoma assigned to a validation cohort. | |
| Control | HCC study 27 (elder; validation) |
| Primary tumor tissue samples obtained from the liver of elder patients (> 40 years old) with hepatocellular carcinoma assigned to a validation cohort. |
stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):-0.88935614Number of Samples:3 / 4
| Experimental | stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
| Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |
HCC study 27 (elder; validation) / HCC study 27 (elder; training)
Relative Expression (log2-ratio):0.8664999Number of Samples:10 / 32
| Experimental | HCC study 27 (elder; validation) |
| Primary tumor tissue samples obtained from the liver of elder patients (> 40 years old) with hepatocellular carcinoma assigned to a validation cohort. | |
| Control | HCC study 27 (elder; training) |
| Primary tumor tissue samples obtained from the liver of elder patients (> 40 years old) with hepatocellular carcinoma assigned to a training cohort. |
oxyphilic adenoma study 1 / normal kidney tissue
Relative Expression (log2-ratio):0.84264374Number of Samples:4 / 2
| Experimental | oxyphilic adenoma study 1 |
| Tumor tissue samples from the kidney of patients with oxyphilic adenoma (renal oncocytoma). | |
| Control | normal kidney tissue |
| Normal fetal kidney tissue samples. |
endometriosis study 6 (minimal/mild endo.; pro. MCP) / normal endometrium tissue (pro. MCP)
Relative Expression (log2-ratio):0.8377819Number of Samples:12 / 20
| Experimental | endometriosis study 6 (minimal/mild endo.; pro. MCP) |
| Endometrial tissue samples from women with minimal or mild endometriosis and pelvic pain and/or infertility collected in the proliferative menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | normal endometrium tissue (pro. MCP) |
| Normal endometrial tissue samples from women collected in the proliferative menstrual cycle phase (MCP). The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. |
influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):-0.8283558Number of Samples:3 / 3
| Experimental | influenza virus study 11 (A/H5N3) |
| Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection. | |
| Control | influenza virus study 4 (A/H1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
Xq12–q13.3 duplication syndrome study 1 / normal lymphoblastoid cell line sample
Relative Expression (log2-ratio):0.81349564Number of Samples:2 / 13
| Experimental | Xq12–q13.3 duplication syndrome study 1 |
| Lymphoblastoid cell line samples from two brothers with Xq12–q13.3 duplication. The patients are affected by severe autism and global developmental delay with multiorgan involvement. | |
| Control | normal lymphoblastoid cell line sample |
| Lymphoblastoid cell line samples from healthy subjects. |